

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. BOX 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.		FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/074,687	02/11/2002		Feng-Jing Chen	6200-0004.20	9747
20551	7590	07/14/2004		EXAMINER	
		& WESTERN, L AST, SUITE 200	CHANNAVAJJALA, LAKSHMI SARADA		
P.O. BOX 12		,	ART UNIT	PAPER NUMBER	
SANDY, U	SANDY, UT 84070				

DATE MAILED: 07/14/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

•	Application No.	Applicant(s)					
Office Action Summer	10/074,687	CHEN ET AL.					
Office Action Summary	Examiner	Art Unit					
	Lakshmi S Channavajjala	1615					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
1) Responsive to communication(s) filed on 10 February 2004.							
2a) This action is FINAL . 2b) This	This action is FINAL . 2b) This action is non-final.						
Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4) ☐ Claim(s) 1-145 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) 1-145 are subject to restriction and/or election requirement.							
Application Papers							
9) The specification is objected to by the Examiner.							
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. § 119							
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
Attachment(s)							
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary (Figure 1997) Interview Summary (Figure 1	e					

Page 2

Applicants' response to previously made election requirement has been received on 2-10-2004. However, upon review the previous election has been withdrawn and a new restriction and election requirement has been made.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

I. Claims 1-133, drawn to pharmaceutical composition, classified in class 424, subclasses 489, 464 and 451.

II. Claims 134-145, drawn to methods, classified in class 424, subclass 464, 489 and 451.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the composition can be used for different methods such as a method of administering the composition to achieve a therapeutic effect in a patient in need thereof, a method of reducing interpatient variability etc., and the method can be practiced with different compositions such as a composition having first and second fractions of an active agent solubilized and suspended or a composition comprising different fractions (solubilized and suspended), wherein the fractions are separated.

Art Unit: 1615

Because these inventions are distinct for the reasons given above and the search required for Group I is not required for Group II, restriction for examination purposes as indicated is proper.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Upon election a group from the above, applicants are further required to elect one species from the following groups:

Group I:

This application contains claims directed to the following patentably distinct species of the claimed invention:

- 1. A pharmaceutical formulation wherein an active agent has a first fraction suspended in a vehicle and a second fraction solubilized in a vehicle.
- 2. A pharmaceutical formulation wherein a first active agent has a first fraction suspended in a vehicle and a second fraction solubilized in a vehicle and additionally a second active agent that is solubilized or suspended in the vehicle.
- 3. A pharmaceutical formulation wherein an active agent has a first fraction suspended in a vehicle and a second fraction solubilized in a vehicle, which is substantially free of added water.
- 4. A pharmaceutical formulation comprising an active agent has a first fraction suspended in a vehicle and a second fraction solubilized in a vehicle, wherein the process of preparing the composition involves the step of coating the interfacial agent on the particles.

Art Unit: 1615

5. A pharmaceutical formulation comprising an active agent has a first fraction suspended in a vehicle and a second fraction solubilized in a vehicle, wherein the composition further comprises a means for segregating the first and second fractions.

Group II:

- 1. A method for reducing the effect of food on absorption ad bioavailability of orally administered agent to a patient.
- 2. A method for increasing the onset f therapeutic effect of an active agent and reducing time to apparent elimination.
- 3. A method for reducing the interpatient variability with respect to absorption and bioavailability

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1 and 134 are generic.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Art Unit: 1615

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lakshmi S Channavajjala whose telephone number is 571-272-0591. The examiner can normally be reached on 7.30 AM -4.00 PM.

Application/Control Number: 10/074,687 Page 6

Art Unit: 1615

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K Page can be reached on 571-272-0602. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Lakshmi S Channavajjala

Examiner

Art Unit 1615

July 8, 2004